To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 450-454

  Karlson, Björn W ^a,b   Palmer, Michael K ^c   Nicholls, Stephen J ^d   Lundman, Pia ^e   Barter, Philip J ^f  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KEELE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e DANDERYD HOSPITAL   (Sweden)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

ACC AHA guidelines; Atorvastatin; Low density lipoprotein cholesterol; Rosuvastatin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DRUG DOSE TITRATION; HUMAN; MEDICAL SOCIETY; META ANALYSIS; PATIENT CODING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED; ODDS RATIO; REGRESSION ANALYSIS; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ATHEROSCLEROSIS; ATORVASTATIN CALCIUM; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; ROSUVASTATIN CALCIUM; SIMVASTATIN; YOUNG ADULT;

EID: 84936755962     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.05.029     Document Type: Article

References (12)

1. Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P.P., Riccardi G., Storey R.F., Wood D. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
2. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. J. Clin. Lipidol. 2014, 8:29-60.
3. Stone N.J., Robinson J., Lichtenstein A.H., Bairey Merz C.N., Lloyd-Jones D.M., Blum C.B., McBride P., Eckel R.H., Schwartz J.S., Goldberg A.C., Shero S.T., Gordon D., Smith S.C., Levy D., Watson K., Wilson P.W. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 ACC/AHA cholesterol guideline. J. Am. Coll. Cardiol. 2014, 63(25 Pt B):2889-2934.
4. Jackevicius C.A. How do the 2013 cholesterol guidelines compare with previous cholesterol guideline reports?. Circ. Cardiovasc Qual. Outcomes 2014, 7:306-310.
5. Nicholls S.J., Brandrup-Wognsen G., Palmer M., Barter P.J. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am. J. Cardiol. 2010, 105:69-76.
6. Karlson B.W., Nicholls S.J., Lundman P., Palmer M.K., Barter P.J. Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients: results from VOYAGER. Atherosclerosis 2013, 228:265-269.
7. Palmer M.K., Nicholls S.J., Lundman P., Barter P.J., Karlson B.W. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. Eur. J. Prev. Cardiol. 2013, 20:1080-1087.
8. Karlson B.W., Barter P.J., Palmer M.K., Lundman P., Nicholls S.J. Comparison of effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. Nutr. Metab. Cardiovasc. Dis. 2012, 22:697-703.
9. Roberts W.C. Two more drugs for dyslipidemia. Am. J. Cardiol. 2004, 93:809-811.
10. Roberts W.C. The rule of 5 and the rule of 7 in lipid-lowering by stain drugs. Am. J. Cardiol. 1997, 80:106-107.
11. Boekholdt S.M., Hovingh G.K., Mora S., Arsenault B.J., Amarenco P., Pedersen T.R., LaRosa J.C., Waters D.D., DeMicco D.A., Simes R.J., Keech A.C., Colquhoun D., Hitman G.A., Betteridge D.J., Clearfield M.B., Downs J.R., Colhoun H.M., Gotto A.M., Ridker P.M., Grundy S.M., Kastelein J.J. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J. Am. Coll. Cardiol. 2014, 64:485-494.
12. Cholesterol treatment trialists' collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.